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Abstract
The most common type of ultrasound contrast agents are encapsulated microbubbles, typically 1–5
microns in diameter. These microbubbles are injected into the bloodstream to provide image
enhancement during an ultrasound exam. Due to their compressibility, these microbubbles are
inherently sensitive to changes in pressure. For imaging, this is beneficial in that these microbubbles
oscillate in an acoustic field and allow imaging systems to detect their response uniquely from tissue.
However, this sensitivity also means that microbubbles can be readily destroyed by significant
hydrostatic pressure. Injection of these microbubbles through a small-gauge catheter, such as
sometimes performed in small animal imaging studies, can result in microbubble destruction. In this
manuscript, the effects of microbubble injection through catheters of varying diameter are examined.
Our results indicate that the concentration and size distribution of microbubbles can be substantially
altered in cases of rapid injection through small needles.
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INTRODUCTION
Ultrasound contrast agents (UCAs) are currently being used in biomedical applications such
as radiology and cardiology (Goldberg et al. 2001). These contrast agents are micron-sized gas
bubbles which are injected intravascularly during an imaging exam. In response to an acoustic
pulse, microbubble contrast agents resonate at a diagnostic ultrasound frequency and improve
the contrast between blood and tissue (Villanueva et al. 1995); (Lang et al. 2006), or highlight
disease or tissue injury (Lindner 2004); (Dayton et al. 2002). A thin shell of lipid, protein, or
polymer is placed around the gas core to stabilize these microbubbles, as unencapsulated gas
would diffuse in milliseconds (Dayton et al. 1999). Although first-generation agents utilized
an air or nitrogen core, current microbubble agents are typically filled with a high-molecular
weight gas such as a perfluorocarbon due to lower gas solubility.
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One of the characteristics of a microbubble contrast agent which makes it highly echogenic is
the ability to resonate in an acoustic pressure field. This property is directly related to the shell
rigidity (Postema et al. 2007). Commercially available agents produce a strong scattered echo
either by oscillating with an intact flexible shell (Chomas et al. 2002); (de Jong et al. 2002),
or by bursting, releasing a free gas bubble which oscillates before it dissolves (Bouakaz et al.
2005); (Chomas et al. 2001); (Frinking et al. 2001). Since these agents are sensitive to an
acoustic pressure field, they are also sensitive to a hydrostatic pressure field. A large change
in hydrostatic pressure will burst many of the microbubbles.
Contrast agent microbubbles are being increasingly used in small animal imaging, particularly
with the development of new high-resolution pre-clinical imaging systems (Foster et al.
2002) and the advancement of molecular imaging (Lindner 2004). Although some small
researchers utilize jugular vein cannulation for contrast administration (Ellegala et al. 2003),
this technique is more complicated and difficult for serial studies. For contrast injection into
small animals, or occasionally in in-vitro studies, many researchers utilize small gauge
catheters/needles with tail vein injection which can result in a large hydrostatic pressure
differential during injection. The literature reports examples of 24 gauge needles used for
injection into rat tail veins (Miller et al. 2007), 27 gauge needles utilized for tail vein injection
into mice (Howard et al. 2006), and 30 gauge needles used for contrast studies of the lymphatic
system (Wisner et al. 2002). Often, researchers do not report infusion rate, although some
reported rates include 0.5 mL/kg/min into rats (Miller et al. 2007), as well as “bolus” injection
into mice and rats (Choi et al. 2007) (Stieger et al. 2006).
In this study, we examine the sensitivity of lipid-shelled microbubbles to injection through
various gauge needles to determine thresholds for contrast injection with minimal bubble
disruption. We examine flow rates from 0.6 ml/minute to 0.5 ml/second to simulate ranges
from fast infusion to rapid bolus injection. In addition to catheter size the injection rates, we
consider microbubble concentration, as it is known that microbubble contrast agents are more
stable in a high concentration. Dilutions of lipid shelled microbubble contrast agents utilized
for small animal imaging reported in the literature cover a wide range, including ~1:10 to ~1:50
(Miller et al. 2007, Stieger et al. 2006).
MATERIALS AND METHODS
Lipid-encapsulated microbubble contrast agents were prepared as previously described
(Borden et al. 2002). Briefly, 1, 2-distearoyl-sn-glycero-3-phosphocholine (DSPC) and 1, 2-
Distearoyl-sn-Glycero-3-Phosphoethanolamine-N-[Methoxy(Polyethylene glycol)-2000]
(DSPE-PEG2000) (Avanti Polar Lipids; Alabaster, AL) were combined at a molar ratio of 9:1,
and suspended in a 0.1 M Tris buffer (Sigma-Aldrich Corp.; Louis, MO). The solution was
placed into sonic bath for 45 min and then aliquoted into gas tight vials to which
decafluorobutane gas was added (SynQuest Labs; Alachua, FL). Microbubbles were formed
by shaking method using a CAPMIX machine (ESPE; Seefeld, Germany) for 45 s.
Microbubble concentrations of approximately 1 · 109, 5 · 108 and 1 · 108 microbubble/ml
(equivalent to ~1:10 to ~1:100 for some lipid-encapsulated perfluorocarbon agents
(http://www.definityimaging.com/pdf/prescribinginfo.pdf) were used. 23, 27 and 30 gauge
needles were used with an addition of 6” polyethylene tubing with diameters matching the
needle gauge. 5 different flow rates (0.01, 0.03, 0.1, 0.3, and 0.5 ml/sec) were provided by a
high precision Harvard Apparatus (Holliston, MA) syringe pump. The microbubble
concentration and size distribution before and after the injection of the microbubbles were
measured with an Accusizer (Particle Sizing Systems Inc.; Santa Barbara, CA). All
experiments were repeated three times.
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The size distribution of microbubbles before injection was approximately 0.95 µm ± 0.75 µm
for all concentrations. Results are separated according to injection needle size.
23-gauge needle
Injection through the 23-gauge needle did not affect either the microbubble concentration or
the size distribution except for the highest flowrate tested. At a flowrate of 0.5 ml/sec, the
percentage of microbubbles destroyed during injection was 70 ± 2 % (Figure 1A) and the mean
diameter of the size distribution was reduced by 10 ± 1 % (Figure 2A) for all concentrations.
27-gauge needle
When 27-gauge needle was used at a 1 · 108 microbubble/ml concentration, more than 85 ± 2
% of the microbubbles were destroyed for flowrates higher than 0.1 ml/sec. At a microbubble
concentration of 5 · 108 microbubble/ml, only 30 ± 3 % microbubble loss was observed for 0.1
ml/sec; however, further increase in the flowrate above 0.3 ml/sec resulted in more than 95 %
microbubble loss. At a microbubble concentration of 1 · 108 microbubble/ml, no destruction
was observed up to 0.1 ml/sec, but 82 ± 3 % and 98 ± 2 % microbubble destruction was observed
for 0.3 and 0.5 ml/sec, respectively (Figure 1B).
The mean diameter of the size distribution dropped more than 10 % with the use of 27-gauge
needle at all microbubble concentrations when the flowrate was more than 0.3 ml/sec. At a
flowrate of 0.1 ml/sec, decrease in mean diameter was observed to be 2, 6 and 10 % at 1 ·
109, 5 · 108 and 1 · 108 microbubble/ml, respectively (Figure 2B).
30-gauge needle
The 30-gauge needle was observed to be destructive to microbubbles at all flow rates tested at
1 · 108 microbubble/ml concentration. More than 55 % of the microbubbles were destroyed at
0.01 ml/sec, and 96 % of the microbubbles were lost for flowrates 0.1 ml/sec and above. With
the use of the 30-gauge needle at both 1 · 109 and 5 · 108 microbubble/ml concentration, 99 %
of the microbubbles were destroyed at flowrates of more 0.1 ml/sec (Figure 1C).
Approximately 15 % reduction in size distribution was observed at all microbubble
concentrations at flowrates above 0.1 ml/sec (Figure 2C). However, at these flow rates – there
were very few contrast agents remaining after being pumped through the catheter.
DISCUSSION
Our results indicate that injection of contrast through a 23-gauge needle was relatively non-
destructive to microbubble contrast agents for all concentrations tested at flow rates up to 300
microliters/sec, which would be a very rapid bolus injection. In contrast, we observed that
injection through a 30-gauge needle was very destructive (>50% loss in concentration) for
contrast agents of 1 · 108 bubbles/ml concentration at all flow rates tested, and very destructive
for 5 · 108 and 1 · 109 bubbles/ml at bolus injection rates > 30 microliters per second.
In addition to destruction of microbubbles, a shift in the mean diameter of the population
towards a smaller diameter was also observed for cases where microbubble loss during
injection was observed. This likely indicated either that large bubbles were destroyed
preferentially, or the population diameter was reduced, possibly by forced compression and
resulting gas loss. Further investigations will elucidate specific mechanisms for these changes.
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This study was largely limited by the fact that only one type of lipid-shelled contrast agent was
tested. However, we anticipate similar trends for the stability of other microbubble type contrast
agents in response to injection parameters.
Maintaining consistency in microbubble population is important in contrast enhanced
ultrasound, particularly in applications where contrast is used for quantitative measurement.
This is complicated further by the fact that the contrast intensity is not always a linear function
of the microbubble concentration (Porter et al. 2003). One application where experimental
consistency might be particularly sensitive to administered concentration is ultrasonic
molecular imaging, where intensity of contrast agents retained at a target site provides
information as to the expression of a specific molecular marker.
Additionally, microbubble concentration has also been found to play an important role in
therapeutic applications, where microbubble concentration has been shown to be related to
efficiency of gene transfection (Zhao et al. 2007) and localized heating (Razansky et al.
2006).
Microbubble concentration is also related to the likelihood of bioeffects, where higher
concentrations are related to increased cavitation (Tu et al. 2006), and differences in the amount
of cavitation based effects may be statistically significant at concentration differences as low
as 1% (Sassaroli and Hynynen 2007). Part of this mechanism may be due to the formation of
larger bubbles as single smaller microbubbles aggregate and then fuse due to secondary
radiation force, which is dependent on concentration (Caskey et al. 2007).
Additionally, microbubble size distribution effects contrast agent behavior. Almost all
properties of a microbubble contrast agent are related to diameter, including echogenicity and
resonant frequency (de Jong et al. 2002, Morgan et al. 2000), susceptibility to radiation force
(Dayton et al. 2002), and potential biodistribution (Talu et al 2008). Thus, size distribution
should be maintained in order to preserve experimental or diagnostic consistency.
CONCLUSIONS
Lipid-coated and perfluorocarbon-filled microbubbles are known to be stable ultrasound
contrast agents. We have shown that the stability of these microbubbles during a contrast
injection depends on needle size, contrast agent concentration, and injection rate. We have
illustrated several combinations of parameters which are non-destructive for contrast injection,
and parameters which will destroy a large majority of the injected dose. Our results indicate
that researchers using contrast injection through a needle or catheter should pay specific
attention to the injection conditions in an imaging study to avoid deleterious affects on the
microbubble contrast agents and to maintain experimental consistency.
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% Microbubble destruction during infusion through a catheter at as a function of flow rate,
concentration, and needle gauge A) 23-gauge, B) 27-gauge, C) 30-gauge.
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% change in mean diameter of microbubble population due to injection as a function of flow
rate, concentration, and needle gauge A) 23-gauge, B) 27-gauge, C) 30-gauge.
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